Biotech startups in the United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Insilico Medicine | Cambridge | Series E | $123.0M | 2025-03-13 |
| Socure | Incline Village | Series E | $156.0M | 2026-08-27 |
| Pathos | New York | Series E | $237.0M | 2026-10-23 |
| Tiny Health | Austin | Series B | $33.0M | 2026-09-29 |
| Colossal Biosciences | Austin | Series C | $60.0M | 2026-02-03 |
| Multiply Labs | San Francisco | Series B | $75.0M | 2026-10-06 |
| Craif | Irvine | Series D | $24.4M | 2026-08-18 |
| Chai Discovery | San Francisco | Series C | $400.0M | 2026-07-14 |
8 rows of the CSV in 5 of its 18 columns.
| Company | Person | Title | Verified email | |
|---|---|---|---|---|
| Prime Movers Lab | A••• K••• | General Partner & Chief Investment Officer - Satori Neuro | a•••@primemoverslab.com | In the CSV |
| AVLab | B••• B••• | Founder, Managing Partner | b•••@analyticsventures.com | In the CSV |
| Eugit Therapeutics, Inc | G••• A••• | General Partner | g•••@ycombinator.com | In the CSV |
3 verified founder and CEO contact rows from organizations on this list, names and emails masked.
- The 4,686 biotech startups in the United States have raised $178.2B in total.
- 618 of them closed their most recent round in the last 12 months, $17.8B combined.
- The largest of those rounds is Chai Discovery's $400.0M Series C, dated July 2026.
- The most recent is Delix Therapeutics' $100.0M Series C on 9 November 2026.
- Y Combinator is an investor in 70 of them, more than any other fund.
- Health care is the most common other sector, with 3,808 companies (81%).
- 30% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 1 to 10 employees (46% of companies with a recorded size).
- 17 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 4,686| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| Zafrens | Zafrens provides a throughput platform that links molecular profiles to cell phenotypes for drug discovery. | Biotech | San Diego | Series A | $6.0M | 2026-11-03 | $35.0M | Liquid 2 Ventures, Global Brain Corporation, BlueYard Capital +2 | 11 to 50 | 2022 |
| Opentrons Unicorn | Opentrons develops pipetting robots that automate laboratory experiments in the life sciences. | Artificial intelligence | Long Island City | Series E | $40.0M | 2026-10-29 | $300.2M | Y Combinator, SOSV, Khosla Ventures +2 | 251 to 500 | 2014 |
| Pathos | Pathos is a biotechnology company that uses AI to speed up oncology drug development. | Artificial intelligence | New York | Series E | $237.0M | 2026-10-23 | $684.0M | New Enterprise Associates, Lightbank, Builders VC +1 | 11 to 50 | 2022 |
| Probably Genetic | Probably Genetic develops treatments aimed at improving the lives of patients with severe, complex diseases. | Artificial intelligence | San Francisco | Series A | $12.0M | 2026-10-15 | $22.9M | Y Combinator, Khosla Ventures, TenOneTen Ventures +2 | 11 to 50 | 2018 |
| Prolific Machines | Prolific Machines develops light-controlled gene expression systems for producing therapeutics. | Artificial intelligence | Emeryville | Series B | $50.0M | 2026-10-14 | $147.0M | SOSV, Mayfield Fund, SOSV SF & NY (Fka IndieBio) +2 | 51 to 100 | 2020 |
| Welltory | Welltory produces AI-powered wellness apps for digital health tracking. | Artificial intelligence | Redwood City | Seed | $2.0M | 2026-10-08 | $16.3M | Goodwater Capital, JOINT JOURNEY, CABRA VC | 51 to 100 | 2016 |
| Multiply Labs | Multiply Labs builds robotic systems that automate biologics manufacturing. | Artificial intelligence | San Francisco | Series B | $75.0M | 2026-10-06 | $97.7M | Y Combinator, Founders Fund, Garage Capital +2 | 11 to 50 | 2016 |
| Biotia | Biotia is a health tech startup that offers AI solutions to diagnose and control infectious diseases. | Artificial intelligence | Long Island City | Series A | $9.0M | 2026-10-01 | $19.7M | Everywhere Ventures, Sand Hill Angels, Tau Ventures +2 | 11 to 50 | 2016 |
| ai3Bio | ai3Bio develops cancer treatments for patients. | Biotech | Pittsburgh | Series A | $48.0M | 2026-09-29 | $103.0M | UPMC Enterprises | 11 to 50 | 2019 |
| Tiny Health | Tiny Health offers at-home microbiome testing and health insights for babies, children, adults, and pregnant people. | Biotech | Austin | Series B | $33.0M | 2026-09-29 | $46.0M | TheVentureCity, Next Coast Ventures, Spero Ventures +2 | 11 to 50 | 2020 |
| Arkea Bio | Arkea Bio develops technology that reduces greenhouse gas emissions from agriculture. | Biotech | Charlestown | Series A | $15.0M | 2026-09-29 | $60.5M | Breakthrough Energy Ventures, Overview, Rabo Ventures | 11 to 50 | 2021 |
| BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
| Ramona | Ramona develops high-throughput microscopy tools for biology labs. | Artificial intelligence | Durham | Series A | $25.0M | 2026-09-22 | $59.7M | National Science Foundation, National Institutes of Health, E14 Fund +1 | 11 to 50 | 2017 |
| Talus Bio | Talus Bio develops AI-driven drugs that target transcription factors considered undruggable. | Artificial intelligence | Seattle | Seed | $11.2M | 2026-09-21 | $27.8M | Y Combinator, Pioneer Fund, National Science Foundation +2 | 11 to 50 | 2020 |
| ImpriMed | ImpriMed provides AI-driven precision medicine services to oncologists and pharmaceutical companies. | Artificial intelligence | Palo Alto | Series A | $10.0M | 2026-09-18 | $44.7M | Plug and Play, Pear VC, Draper Associates +1 | 51 to 100 | 2017 |
| Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco | Series E | $92.5M | 2026-09-16 | $300.0M | Mission BioCapital, Pfizer, The Column Group +1 | 11 to 50 | 2012 |
| Evia Bio | Evia Bio develops non-DMSO cryopreservation solutions for life sciences. | Biotech | Minneapolis | Series A | $5.5M | 2026-09-16 | $5.7M | Newchip Accelerator, Pleasant Bay Capital Partners, Walleye Tank | 1 to 10 | 2019 |
| Evvy | Evvy offers an AI-driven precision medicine platform focused on women's health. | Artificial intelligence | New York | Series B | $40.0M | 2026-09-15 | $59.0M | General Catalyst, BoxGroup, Left Lane Capital +2 | 11 to 50 | 2021 |
| Mithrl | Mithrl is a software development company that builds custom NGS data workflows on demand. | Artificial intelligence | San Francisco | Series A | $20.0M | 2026-09-15 | $24.0M | Bonfire Ventures | 51 to 100 | 2023 |
| heXem bio | HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells and extend healthy lifespan. | Biotech | New York | Seed | $10.4M | 2026-09-15 | $10.4M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| PGxAI | PGxAI provides a clinical decision support platform for pharmacogenomics, medication safety, and real-world evidence. | Artificial intelligence | Palo Alto | Seed | $3.0M | 2026-09-14 | $5.0M | ATEM Capital Fund LP | 11 to 50 | 2023 |
| Alzheon | Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. | Biotech | Framingham | Series F | $78.8M | 2026-09-10 | $343.3M | Ally Bridge Group, National Institute on Aging | 11 to 50 | 2013 |
| TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Palo Alto | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| Navion Neurosciences | Navion Neurosciences develops sodium channel therapeutics for neurological diseases at a pre-clinical stage. | Artificial intelligence | Charlottesville | Seed | $10.8M | 2026-09-09 | $21.2M | Virginia Innovation Partnership Corporation, 3B Future Health Fund, UVA Licensing & Ventures Group +1 | 1 to 10 | 2021 |
| Moonwalk Biosciences | Moonwalk Biosciences develops precision epigenetic medications through its genomic medicine platform. | Artificial intelligence | South San Francisco | Series B | $70.0M | 2026-09-08 | $127.0M | Google Ventures, Khosla Ventures, ARCH Venture Partners +2 | 11 to 50 | 2022 |
| Cloverleaf Bio | Cloverleaf Bio develops an RNA therapeutic platform for oncology. | Biotech | New Haven | Seed | $33.0M | 2026-09-08 | $33.0M | Mission BioCapital | 1 to 10 | 2023 |
| INIA Biosciences | INIA Biosciences develops non-invasive, home-administered medical devices to manage chronic inflammatory diseases. | Biotech | Boston | Seed | $1.5M | 2026-09-08 | $1.5M | MassChallenge, MedTech Innovator | 1 to 10 | 2020 |
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| N-Power Medicine | N-Power Medicine is a biotechnology company that uses AI to offer clinical research and drug development services. | Artificial intelligence | Redwood City | Series B | $32.0M | 2026-09-01 | $104.0M | Merck Global Health Innovation Fund | 101 to 250 | 2021 |
Table 1. Biotech startups in the United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 4,686.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| 2 | Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| 3 | Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| 4 | Pathos | Pathos is a biotechnology company that uses AI to speed up oncology drug development. | Artificial intelligence | New York | Series E | $237.0M | 2026-10-23 | $684.0M | New Enterprise Associates, Lightbank, Builders VC +1 | 11 to 50 | 2022 |
| 5 | Socure Unicorn | Socure provides digital identity verification, fraud prevention, and regulatory compliance software. | Artificial intelligence | Incline Village | Series E | $156.0M | 2026-08-27 | $900.4M | Accel, Citi Ventures, JP Morgan +1 | 501 to 1,000 | 2012 |
| 6 | Angitia Biopharmaceuticals | Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. | Biotech | Westlake Village | Series D | $130.0M | 2026-02-05 | $406.0M | Legend Capital, OrbiMed, Oriza Holdings +1 | 51 to 100 | 2018 |
| 7 | Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| 8 | Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management, Novo Holdings, Janus Henderson Investors +1 | 1 to 10 | 2018 |
| 9 | Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| 10 | Bridge to Life | Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. | Biotech | Northbrook | Series C | $110.0M | 2026-08-12 | $167.5M | Perceptive Advisors | 101 to 250 | 2005 |
Table 2. Biotech startups in the United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Y Combinator | Startup accelerator | Mountain View, United States | 70 | 1% | 14 | Opentrons, Probably Genetic, Multiply Labs |
| 2 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 49 | 1% | 10 | Ramona, Talus Bio, Remedium Bio |
| 3 | Alumni Ventures | Angel group | Manchester, United States | 36 | 1% | 6 | Century Health, ParcelBio, Modicus Prime |
| 4 | SOSV | Venture capital firm | Princeton, United States | 33 | 1% | 12 | Opentrons, Prolific Machines, heXem bio |
| 5 | RA Capital Management | Startup incubator | Boston, United States | 32 | 1% | 6 | Delix Therapeutics, Superluminal Medicines, Claris Biotherapeutics |
| 6 | SOSV SF & NY (Fka IndieBio) | Venture capital firm | San Francisco, United States | 28 | 1% | 11 | Prolific Machines, heXem bio, Farm Minerals |
| 7 | OrbiMed | Private equity firm | New York, United States | 25 | 1% | 6 | Triveni Bio, Terremoto Biosciences, Angitia Biopharmaceuticals |
| 8 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 24 | 1% | 5 | TwoStep Therapeutics, Lycia Therapeutics, Triveni Bio |
| 9 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 20 | 0% | 1 | BigHat Biosciences |
| 10 | National Institutes of Health | Entrepreneurship program | Bethesda, United States | 20 | 0% | 4 | Ramona, Talus Bio, Terrestrial Bio |
| 11 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 20 | 0% | 2 | Moonwalk Biosciences, Mirador Therapeutics |
| 12 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 19 | 0% | 7 | Opentrons, Probably Genetic, Moonwalk Biosciences |
| 13 | Techstars | Startup accelerator | New York, United States | 19 | 0% | 2 | Kimba, Modicus Prime |
| 14 | Plug and Play | Startup accelerator | Sunnyvale, United States | 19 | 0% | 6 | ImpriMed, Prellis Biologics, WittGen Biotechnologies |
| 15 | Google Ventures | Corporate venture arm | San Francisco, United States | 18 | 0% | 4 | Moonwalk Biosciences, Cerevance, Prudentia Sciences |
Table 3. Biotech startups in the United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 3,808 | 81% | $158.4B |
| Software | 810 | 17% | $28.5B |
| Artificial intelligence | 513 | 11% | $20.9B |
| Hardware | 169 | 4% | $5.4B |
| Energy | 52 | 1% | $1.1B |
| Fintech | 50 | 1% | $2.0B |
| Cybersecurity | 49 | 1% | $1.7B |
| Commerce | 31 | 1% | $299.1M |
| Education | 27 | 1% | $156.2M |
Table 4. Biotech startups in the United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in the United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 396 | 8% |
| Cambridge | 272 | 6% |
| New York | 263 | 6% |
| San Diego | 231 | 5% |
| Boston | 211 | 5% |
| Palo Alto | 87 | 2% |
| Seattle | 86 | 2% |
| South San Francisco | 69 | 1% |
| Houston | 61 | 1% |
| Berkeley | 57 | 1% |
| Los Angeles | 56 | 1% |
| Austin | 52 | 1% |
Table 6. Biotech startups in the United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 8 | 1% | $185.3M |
| October 2026 | 50 | 8% | $1.7B |
| September 2026 | 71 | 11% | $2.2B |
| August 2026 | 54 | 9% | $1.5B |
| July 2026 | 44 | 7% | $1000.0M |
| June 2026 | 58 | 9% | $2.2B |
| May 2026 | 51 | 8% | $844.5M |
| April 2026 | 39 | 6% | $918.1M |
| March 2026 | 50 | 8% | $1.0B |
| February 2026 | 40 | 6% | $959.7M |
| January 2026 | 76 | 12% | $2.9B |
| December 2025 | 58 | 9% | $1.6B |
| November 2025 | 19 | 3% | $697.5M |
Table 7. Biotech startups in the United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 541 | 12% | $15.5B |
| 2025 | 513 | 11% | $14.3B |
| 2024 | 391 | 8% | $11.9B |
| 2023 | 367 | 8% | $8.2B |
| 2022 | 378 | 8% | $8.9B |
| 2021 | 408 | 9% | $14.6B |
Table 8. Biotech startups in the United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 627 | 14% |
| 2020 to 2022 | 775 | 17% |
| 2015 to 2019 | 1,376 | 30% |
| 2010 to 2014 | 847 | 18% |
| Before 2010 | 979 | 21% |
Table 9. Biotech startups in the United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2,074 | 46% |
| 11 to 50 | 1,798 | 40% |
| 51 to 100 | 365 | 8% |
| 101 to 250 | 165 | 4% |
| 251 to 500 | 47 | 1% |
| 501 to 1,000 | 40 | 1% |
| 1,001 to 5,000 | 14 | 0% |
| 5,001 to 10,000 | 7 | 0% |
| 10,001 or more | 20 | 0% |
Table 10. Biotech startups in the United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in the United States. On 16 November 2026 that is 4,686 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 4,686 rows: 925 have no round amount, 0 no city and 817 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in the United States are on the list?
- 4,686, in the file dated 16 November 2026. 618 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 4,686 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.